FORMYCON AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.95 EUR | +0.63% |
|
+3.36% | -29.17% |
| Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 319 | 530 | 651.7 | 1,309 | 904.6 | 705.5 | - | - |
| Enterprise Value (EV) 1 | 296.6 | 487.8 | 626.6 | 1,648 | 904.6 | 634.9 | 630.7 | 576.8 |
| P/E ratio | -139 x | -98.4 x | -48.4 x | 33.4 x | 11.9 x | -74 x | 521 x | 14.1 x |
| Yield | - | - | - | - | - | - | 0.61% | - |
| Capitalization / Revenue | 9.41 x | 15.5 x | 17.6 x | 30.8 x | 11.6 x | 11.6 x | 9.97 x | 4.61 x |
| EV / Revenue | 8.75 x | 14.3 x | 17 x | 38.8 x | 11.6 x | 10.5 x | 8.91 x | 3.77 x |
| EV / EBITDA | -212 x | -101 x | -50.6 x | -104 x | 596 x | -38.5 x | 37.1 x | 6.03 x |
| EV / FCF | -123 x | -86.1 x | -42.1 x | -36.1 x | - | -21.5 x | -221 x | 57.7 x |
| FCF Yield | -0.81% | -1.16% | -2.38% | -2.77% | - | -4.65% | -0.45% | 1.73% |
| Price to Book | 6.62 x | 8.57 x | 11.6 x | 3.67 x | - | 1.24 x | 1.2 x | 1.08 x |
| Nbr of stocks (in thousands) | 10,000 | 10,000 | 11,047 | 15,130 | 16,039 | 17,660 | - | - |
| Reference price 2 | 31.90 | 53.00 | 59.00 | 86.50 | 56.40 | 39.95 | 39.95 | 39.95 |
| Announcement Date | 5/18/20 | 5/17/21 | 5/18/22 | 4/27/23 | 4/25/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 33.9 | 34.23 | 36.96 | 42.5 | 77.7 | 60.73 | 70.75 | 152.9 |
| EBITDA 1 | -1.4 | -4.81 | -12.39 | -15.87 | 1.518 | -16.5 | 17 | 95.67 |
| EBIT 1 | -2.3 | -5.725 | -13.33 | -17.73 | -0.369 | -24.6 | 4.05 | 73.53 |
| Operating Margin | -6.78% | -16.73% | -36.07% | -41.72% | -0.47% | -40.5% | 5.72% | 48.09% |
| Earnings before Tax (EBT) 1 | -2.291 | -5.923 | -13.47 | 36.6 | 79.07 | -9.433 | 6.7 | 94.85 |
| Net income 1 | -2.293 | -5.926 | -13.48 | 35.99 | 75.8 | -12.35 | 11.42 | 70.95 |
| Net margin | -6.76% | -17.31% | -36.46% | 84.69% | 97.55% | -20.33% | 16.15% | 46.4% |
| EPS 2 | -0.2293 | -0.5387 | -1.218 | 2.590 | 4.720 | -0.5400 | 0.0767 | 2.830 |
| Free Cash Flow 1 | -2.403 | -5.662 | -14.88 | -45.64 | - | -29.5 | -2.85 | 10 |
| FCF margin | -7.09% | -16.54% | -40.26% | -107.39% | - | -48.57% | -4.03% | 6.54% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 10.45% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 14.09% |
| Dividend per Share 2 | - | - | - | - | - | - | 0.2433 | - |
| Announcement Date | 5/18/20 | 5/17/21 | 5/18/22 | 4/27/23 | 4/25/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | 1.804 |
| Net margin | - |
| EPS 2 | 0.1130 |
| Dividend per Share | - |
| Announcement Date | 8/30/23 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 339 | - | - | - | - |
| Net Cash position 1 | 22.4 | 42.2 | 25.2 | - | - | 70.7 | 74.9 | 129 |
| Leverage (Debt/EBITDA) | - | - | - | -21.36 x | - | - | - | - |
| Free Cash Flow 1 | -2.4 | -5.66 | -14.9 | -45.6 | - | -29.5 | -2.85 | 10 |
| ROE (net income / shareholders' equity) | -5.63% | -10.2% | -21.7% | 17.5% | - | -1.83% | 1% | 8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 4.820 | 6.190 | 5.070 | 23.60 | - | 32.30 | 33.30 | 37.00 |
| Cash Flow per Share 2 | - | -0.4600 | -1.280 | -1.380 | - | -1.140 | 1.160 | - |
| Capex 1 | 0.92 | 0.56 | 0.7 | 26.8 | - | 25.7 | 30.2 | 38.2 |
| Capex / Sales | 2.72% | 1.63% | 1.9% | 62.97% | - | 42.32% | 42.65% | 24.97% |
| Announcement Date | 5/18/20 | 5/17/21 | 5/18/22 | 4/27/23 | 4/25/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
39.95
EUR
Average target price
94.2
EUR
Spread / Average Target
+135.79%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.17% | 753M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- FYB Stock
- Financials Formycon AG
